Scopoletin inhibits α-glucosidase in vitro and alleviates postprandial hyperglycemia in mice with diabetes

Eur J Pharmacol. 2018 Sep 5:834:152-156. doi: 10.1016/j.ejphar.2018.07.032. Epub 2018 Jul 19.

Abstract

The aim of this study was to investigate whether scopoletin could inhibit the activities of the carbohydrate digestive enzymes, α-glucosidase and α-amylase, and reduce postprandial hyperglycemia in streptozotocin (STZ)-induced diabetes in mice. Scopoletin showed a distinct inhibitory effect on α-glucosidase and α-amylase. The half maximal inhibitory concentration (IC50) of scopoletin was 85.12 and 37.36 μM for α-glucosidase and α-amylase, respectively, which were lower values than those for acarbose. The increase in postprandial blood glucose levels was significantly suppressed in the scopoletin group compared to the control group of STZ-induced diabetes in mice. Moreover, the area under the curve significantly decreased with the administration of scopoletin in STZ-induced diabetes in mice. These results showed that scopoletin might help to lower postprandial hyperglycemia through inhibition of carbohydrate digestive enzymes.

Keywords: Diabetic mice; Postprandial hyperglycemia; Scopoletin; α-amylase; α-glucosidase.

MeSH terms

  • 3T3 Cells
  • Animals
  • Blood Glucose / metabolism
  • Cell Survival / drug effects
  • Diabetes Mellitus, Experimental / complications*
  • Glycoside Hydrolase Inhibitors / pharmacology*
  • Glycoside Hydrolase Inhibitors / therapeutic use
  • Hyperglycemia / blood
  • Hyperglycemia / complications*
  • Hyperglycemia / drug therapy*
  • Male
  • Mice
  • Mice, Inbred ICR
  • Scopoletin / pharmacology*
  • Scopoletin / therapeutic use
  • alpha-Amylases / antagonists & inhibitors
  • alpha-Glucosidases / metabolism*

Substances

  • Blood Glucose
  • Glycoside Hydrolase Inhibitors
  • alpha-Amylases
  • alpha-Glucosidases
  • Scopoletin